|Key people||Brenton L. Saunders, CEO of Forest Laboratories|
Aptalis is a wholly owned subsidiary of Forest Laboratories that develops, manufactures, markets, and distributes a broad line of gastrointestinal (GI) and specialty products, primarily in North America and Europe. Aptalis has manufacturing sites in Canada, Italy, the US, and France.
Aptalis was formed in 2011 after the acquisition of Eurand Pharmaceuticals by Montreal-based Axcan Pharma. Axcan's area of specialty was the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008. Eurand Pharmaceuticals was a producer and contract manufacturer of modified release or taste-masked pharmaceutical dosage forms. Eurand's former manufacturing facilities in Vandalia, Ohio and Milan, Italy continued to operate under the Aptalis name.
- "Company Overview of Aptalis Pharma Inc.". Retrieved 2012-03-08.
- "Press Release: The Newly Combined Axcan and Eurand Announce Name Change to Aptalis". Retrieved 14 February 2012.
- "Press Release:Eurand to be Acquired by Axcan for $12.00 per Share in Cash". Retrieved 14 February 2012.
- "Press Release: Axcan Announces Completion of Transaction With TPG Capital". Retrieved 3 December 2010.
- "Press Release: Forest Labs to Buy Aptalis for $2.9 Billion". Retrieved 8 January 2014.
- "Aptalis Holdings offcially withdraws IPO following announcement of acquisition by Forest Labs". Retrieved 5 February 2014.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|